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ABSTRACT 
The subtle hypoxia underlying chronic cardiovascular disease is an attractive target for PET 
imaging, but the lead hypoxia imaging agents 64CuATSM and 18FMISO trapped only at extreme 
levels of hypoxia and hence are insufficiently sensitive for this purpose. We have therefore 
sought an analog of 64CuATSM better suited to identify compromised but salvageable 
myocardium, validated using parallel biomarkers of cardiac energetics comparable to those 
observed in chronic cardiac ischemic syndromes. 
Methods: Rat hearts were perfused with aerobic buffer for 20 min, followed by a range of 
hypoxic buffers (using a computer-controlled gas mixer) for 45 min. Contractility was monitored 
by intraventricular balloon, energetics by 31P NMR spectroscopy, lactate and creatine kinase 
release spectrophotometrically, and HIF1α by Western blotting.  
Results: We identify a key hypoxia threshold at a 30% buffer O2 saturation which induces a 
stable and potentially survivable functional and energetic compromise: LV developed pressure 
was depressed by 20%, and cardiac phosphocreatine was depleted by 65.5 ± 14% (p<0.05 vs 
control), but ATP levels were maintained. Lactate release was elevated (0.21 ± 0.067 versus 
0.056 ± 0.01 mmol/L/min, p<0.05), but not maximal (0.46 ± 0.117 mmol/L/min), indicating 
residual oxidative metabolic capacity. HIF1α was elevated, but not maximal. At this key 
threshold, 64CuCTS selectively deposited significantly more 64Cu than any other tracer we 
examined (61.8 ± 9.6% injected dose versus 29.4 ± 9.5% for 64CuATSM p<0.05).  
Conclusion: The hypoxic threshold which induced survivable metabolic and functional 
compromise was 30% O2. At this threshold, only 64CuCTS delivered a hypoxic:normoxic contrast 
of 3:1, and it therefore warrants in vivo evaluation for imaging chronic cardiac ischemic 
syndromes. 
 
Keywords- Cardiac hypoxia, PET, NMR, bioenergetics, Cu-ATSM, bis(thiosemicarbazones) 
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INTRODUCTION 
Hypoxia is a major factor in the pathology of cardiac ischemia. It is an important factor in the 
etiology of microvascular disease and cardiac hypertrophy, the prime determinant of the 
progression to heart failure, and the driver for compensatory angiogenesis 1-3. In microvascular 
disease, while gross perfusion measured by MRI or scintigraphy may appear normal, the 
myocardium is hypoxically compromised at the cellular level 4.  This makes it an extremely 
difficult condition to diagnose, currently assigned by exclusion of other pathologies 5. In 
hypertrophic myocardium, perfusion is also often “normal”, but increased cell size, loss of t-
tubules, and scar means that increased diffusion distances critically limit oxygen delivery to 
mitochondria 6, 7. To accurately characterise these conditions, imaging disparities between 
supply and demand for blood flow (ischemia), or O2 (hypoxia), would be a potentially more 
useful approach than measuring poor perfusion per se 8, but as yet, there are no methodologies 
sufficiently sensitive or specific for this purpose 9, 10. 
The PET tracer 64CuATSM (R1=R3=R4=R6=Me, R2=R5=H, Fig 1), exhibits rapid first pass uptake 
and fast clearance from normoxic tissues 11 and blood 12, and rapid retention in hypoxic tissues 
to generate excellent images of tissue hypoxia within minutes. Experimentally, tissue 64Cu 
accumulation from 64CuATSM has been demonstrated only in extreme models of acute hypoxia 
and ischemia in isolated perfused hearts, and in regionally occluded canine myocardium in vivo 
13, 14, appearing to have a hypoxia-selective threshold of 1mm Hg or lower 11, 15. While this 
degree of hypoxia is compatible with the survival and radio-resistance of cancer cells, for which 
it was designed, it is too severe for the long-term survival of cardiac myocytes (normal cardiac 
mitochondrial pO2 is 10-35 mm Hg) 16. In the one very small (seven patient) cardiac clinical trial 
that has been performed to date using 62CuATSM, 62Cu accumulation was only visualised in the 
myocardium of one patient with unstable angina, despite four of those patients exhibiting 
increased regional 18FDG uptake 12. Thus, while CuATSM can be used to selectively identify the 
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extreme acute hypoxia commonly induced in experimental models, it seems insufficiently 
sensitive to detect the subtle hypoxia characterising the chronic cardiac ischemic syndromes 
that are currently difficult to identify 9.  
 
The fundamental challenge, therefore, is to identify complexes which deposit their radiocopper 
payload within the myocardium at less extreme levels of hypoxia where its biochemistry is 
perturbed, but remains potentially salvageable. We reason that this target hypoxia “threshold” 
would be the point where there remains a degree of metabolic flexibility: a compromised but 
functional capacity for oxidative metabolism, but with sufficient ATP turnover to maintain ionic 
homeostasis and cellular integrity 9. We have therefore performed a series of hypoxia titrations 
in the isolated heart to determine where this threshold lies using a panel of biochemical and 
biophysical assays. We then use a recently developed gamma detection array 17 to identify 
analogs of 64CuATSM exhibiting greater sensitivity to hypoxia at this more relevant threshold. 
 
MATERIALS AND METHODS 
Reagents and Animals 
All reagents were purchased from Sigma unless otherwise stated.  Gases were supplied by 
BOC. Desired gas mixtures (O2/N2/CO2) were achieved using a GSM-3 gas mixer (CWE Inc). 
 
Male Wistar rats (275-300 g, Harlan), fed ad libitum, were used for all experiments. Animal 
procedures were in accordance with the Animals (Scientific Procedures) Act UK (1986). 
 
Experimental Protocol 
64Cu was produced and used to radiolabel 2,3-butanedione bis (thiosemicarbazone) (ATS), 
diacetyl-bis(N4-ethylthiosemicarbazone) (ATSE), 2,3-butanedione bis(N4-
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methylthiosemicarbazone) (ATSM) and 2,3-pentanedione bis(thiosemicarbazone) (CTS) as 
previously described 17. 
Rats (n = 6/group) were anesthetized with Sagatal (100 mg ip) and heparinized (200 IU ip), their 
hearts excised and cannulated in the Langendorff mode 18. Hearts were perfused at constant 
flow (to simplify pharmacokinetic modeling) of 14 ml/min with a modified Krebs-Henseleit buffer 
(KHB) described previously 17, gassed with 95% O2/5% CO2 gas mixture, and contractile 
function was measured with a left ventricular balloon. Perfusion pressure was monitored by a 
pressure transducer in the arterial line. Hearts were paced at 300 beats/min throughout. 
 
After 20 minutes, perfusate delivery was switched to a second reservoir containing KHB 
equilibrated with a gas mixture containing either 95%, 40%, 30%, 20%, 10% or 0% O2, balanced 
with N2 and 5% CO2 (for pH buffering), delivered by a gas mixer. 1 ml aliquots of coronary 
effluent were collected at regular intervals, and analysed for lactate content (YSI 2300 STAT 
Plus™ lactate analyser) to identify the onset of anerobic glycolysis, and creatine kinase content 
to monitor tissue necrosis. At the end of each experiment, hearts were snap-frozen in liquid 
nitrogen prior to Western blotting for HIF1α. 
 
31P Magnetic Resonance Spectroscopic Analysis (MRS) 
Hearts were cannulated and inserted into a 15 mm glass MRS tube which was then placed in a 
custom-built MRS probe, as previously described 19. 31P MRS spectra were acquired on a 
Bruker Avance III 9.4T spectrometer using a 15 mm 31P/1H birdcage coil 20. Shimming was 
performed on the 1H lineshape of water (FWHM < 20 Hz). 31P spectra were acquired with a 
pulse-acquire sequence using a 60o flip angle, repetition time of 3.8 s and 64 scans (4 minutes 
per spectrum). The peak area of each metabolite was normalized to that of phosphocreatine 
(PCr) during normoxia. 
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Profiling of Radiotracer Retention and Elution 
In parallel groups of hearts, radiotracer uptake and pharmacokinetics were monitored using a 
custom built “triple gamma detector system” 17, consisting of three orthogonally positioned lead-
shielded NaI detectors interrogating the arterial input line, the heart, and the venous outflow 
lines respectively, each connected to a modified GinaSTAR™ instant thin layer chromatography 
system (Raytest Ltd).  100 µl boluses containing 1 MBq radiotracer were injected into the 
arterial line after 10 minutes of normoxia, and 5 and 25 minutes of hypoxia. Time-activity curves 
generated by the GinaSTAR™ were imported into MATLAB® (MathWorks®). Data were decay-
corrected and normalized to the maximum value of each group. Tissue retention was calculated 
as the residual activity in the heart 20 minutes post-injection as a percentage of the peak activity 
(% injected dose, %ID), as previously described 21. 
 
Western Blotting 
Hearts were homogenized in 10 ml of homogenization buffer / g tissue (100 mM Tris pH 7.4, 2 
mM sodium vanadate, 5 mM sodium fluoride, 1 x protease inhibitor cocktail tablet / 50 ml, 4oC). 
Equal volumes of homogenate and 2 x sodium dodecyl sulphate sample buffer were mixed 
before being loaded and separated by molecular weight using SDS-PAGE on a 10% 
polyacrylamide gel. Proteins were transferred to PVDF membranes (0.45 µm; GE Healthcare) 
using semi-dry blotting (Biorad). Blots were incubated for 2 hours at room temperature with 
hypoxia inducible factor (HIF-1α) antibody (rat polyclonal 5 µg/ml; Abcam). After incubation with 
HRP-labeled secondary antibodies, blots were developed using enhanced chemiluminescence 
(Amersham Pharmacia Biotech), with GAPDH as a loading control. HIF-1α and GAPDH 
expression were quantified through film-scanning and densitometry using Quantity One 
software (Biorad), with HIF-1α normalized to GAPDH. 
 
Statistical Analysis 
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Analyses were performed using GraphPad Prism® (GraphPad Software Inc). All values are 
expressed as the mean±SD. A paired t-test was used for all pair-wise comparisons, and one 
way ANOVA with the Bonferroni correction for multi-way comparisons. Dunnett’s post analysis 
test was applied when multiple comparisons were made to a control group.
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RESULTS 
All tracers examined deposited increasing amounts of radiocopper in the myocardium with 
increasingly severe hypoxia (Fig 2). Hypoxia selectivity was apparent within 5 minutes of onset 
(Fig 2a), with significant 64Cu retention in hearts injected with 64CuCTS with KHB equilibrated 
with 30% O2 (40.9 ± 4.6% ID versus 13.7 ± 3.1% pre-hypoxia p<0.05), with an EC50 value of 
32.1% O2. While the other tracers also exhibited hypoxia selectivity, they were less sensitive; 
64Cu ATSM and 64Cu ATSE were only selective at the 20% O2 threshold (31.3 ± 1.42 and 
39.34% ID, EC50 values of 18.9 and 22.9% O2 respectively), while 64CuATS was only selective 
at the 10% O2 threshold (34.7 ± 12.7% ID, EC50 7.4% O2). The same selectivities were evident 
after 25 minutes (Figure 2b), although the absolute amount of radiocopper deposition in each 
case was greater. 64CuCTS was the only tracer to selectively deposit radiocopper in the heart at 
30% O2 (61.8 ± 9.6% versus 15.8 ± 3.8% ID in normoxic hearts (p<0.05), EC50 32% O2), and 
consistently more than 64CuATSM under all hypoxic conditions. The selectivity profiles of 
64CuATSM, 64CuATSE and 64CuATS were largely similar (EC50 values of 25.2, 25.1 and 22.2% 
O2 respectively), although 64CuATS deposited significantly more 64Cu than 64CuATSM at 0% O2 
(78 ± 7.2% versus 63.4 ± 11.5; p<0.05). 
 
The critical threshold for decreasing LVDP within 5 minutes was 20% O2, (to 68 ± 14 mm Hg 
from a pre-hypoxia 145 ± 12 mm Hg; p<0.05, Fig 3a), although perfusion pressure and LVEDP 
were unaffected. Perfusion with 30% O2 KHB elevated LVEDP above pre-ischemic values after 
25 minutes (36 ± 8 versus 5 ± 3 mm Hg; p<0.05), while perfusion pressure was only elevated 
within this timeframe by completely anoxic KHB (112 ± 12 versus 73 ± 9 mm Hg; p<0.05).  
 
Representative 31P NMR spectra from a heart perfused with 0% O2 KHB are shown in fig 4A. 
PCr was depleted by ~20 minutes of hypoxia, with a concomitant increase in inorganic 
phosphate (Pi). Sugar phosphates became apparent within 8 minutes, and by 25 minutes, ATP 
by King's College London on May 18, 2015. For personal use only. jnm.snmjournals.org Downloaded from 
9 
 
levels were compromised.  30% O2 KHB decreased cardiac PCr within 5 minutes (to 65.5 ± 14% 
of pre-hypoxia; p<0.05, Fig 4B), while PCr was only compromised by 40%O2 after 25 minutes 
(to 43.4 ± 1.4%; p<0.05).  ATP levels were unaffected by 30% O2 KHB, but were depleted by 
20% O2 KHB (from 66.8 ± 20% to 41.8 ± 17%; p<0.05, Fig 4C); perfusion with more hypoxic 
buffers achieved no greater degree of ATP loss. Sugar and inorganic phosphates were not 
elevated by hypoxia after 5 minutes, but accumulated after 25 minutes perfusion with 20% O2 
(116 ± 37% versus 60 ± 18% and 49.8 ± 22.2% versus 13.8 ± 10.3% respectively; p<0.05). 
While lactate washout was evident after 25 minutes of perfusion with 30% O2 KHB, (0.21 ± 0.07 
versus 0.01 ± 0.02 nmol during normoxia; p<0.05 (Fig 5A), it increased further with 20% O2 KHB 
to a near-maximal value of 0.46 ± 0.11 (p<0.05). There was no evidence of creatine kinase 
leakage in any experimental group (data not shown). HIF-1α:GAPDH expression was elevated 
after 25 minutes of 30% O2 KHB (0.278 ± 0.064 versus normoxic 0.175 ± 0.047; p<0.05, Fig 
5B), rising to a maximum of 0.61 ± 0.08 with 0% O2 KHB.  
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DISCUSSION 
We recently demonstrated that 64CuCTS and its analog 64CuATS exhibit significantly greater 
hypoxia selectivity than the current lead compound 64CuATSM in hearts perfused with hypoxic 
(0% O2) buffer 17. While a promising first step in the screening process, the key to the 
progression of this class of compounds is to identify complexes selective for levels of hypoxia 
which correlate with survivable (and treatable) cardiac disease 9, 10. The relative sensitivities of 
these complexes to pathophysiologically relevant degrees of cardiac hypoxia were unknown. In 
this study, we identify a key hypoxic threshold that induces the major hallmarks of compromised 
but salvageable myocardium, which are: depressed contractile function, compromised PCr 
levels (but stable ATP levels), elevated HIF-1α expression, and increased but not maximal 
lactate washout (indicating residual oxidative reserve). At this threshold, achieved by perfusion 
with KHB saturated with 30%O2, we demonstrate that 64CuCTS is the only complex among the 
four evaluated that provides a hypoxic:normoxic tissue contrast which would be exploitable for 
PET imaging 9. 
Our approach, of identifying parallel biomarkers of biochemical compromise to correlate against 
tracer uptake circumvents the difficult problem of describing tracer uptake in terms of absolute 
(and potentially arbitrary) intracellular oxygen concentrations, which are not only difficult to 
determine, but would also vary in relevance dependent upon oxygen demand, cardiac workload, 
and experimental model 16. It also allows an immediate bioenergetic interpretation of the 
relevance of increased cardiac tracer retention, which is arguably translatable from the 
Langendorff perfused heart to the clinical situation.  While changes in cardiac energetics can be 
quantified by 31P spectroscopic imaging in clinical MR systems, the technical capacity and 
infrastructure to do so is not widespread, requires significant expertise, long acquisition times, 
and results in images of poor spatial resolution. Correlating PET tracer uptake with these key 
changes in cardiac energetics could therefore provide the same biochemical insight as 31P MR 
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spectroscopic imaging, but exploit a technically simpler imaging approach with significantly 
greater temporal and spatial resolution (typical voxel sizes for clinical 64Cu PET are 65 mm3 22, 
compared to 560 mm3 for 31P MRI at 3T) 23.  
We demonstrate that perfusion of hearts with 30% O2 saturated KHB significantly depleted PCr, 
but was sufficient to maintain intracellular ATP and a degree of contractility. These 
characteristics mirror the reductions in PCr:ATP ratio previously demonstrated by 31P MRS in 
patients with heart failure 24,25 and hypertrophic cardiomyopathy 26, and correlate with declining 
left ventricular ejection fraction and increased mortality 27. While moderate depletion of cardiac 
ATP has also been observed in patients diagnosed with hypertrophied and failing myocardium 
28, we used a less severe experimental threshold where PCr levels were compromised, but ATP 
levels were maintained to provide a more sensitive means of screening for diagnostically 
relevant hypoxia-selective complexes. Crucially, while 30% O2 KHB increased lactate release by 
the heart, the rate of lactate washout only became maximal when hearts were perfused with 
KHB equilibrated with 20% O2 and below, suggesting that at 30% O2 there was still an aerobic 
metabolic reserve. At this key threshold, therefore, cardiac energetics and contractile function 
were compromised, but there was residual oxidative metabolism (and by inference 
mitochondrial function), suggesting that this degree of hypoxia would be sustainable chronically, 
making it a reasonable model of chronic cardiac ischemia.  
30% O2 was also the threshold for increased intracellular HIF-1α. As the key regulator of 
hypoxic gene expression, HIF-1α is responsible for numerous acute and chronic adaptive 
responses to tissue hypoxia, ranging from elevated glucose uptake and altered calcium 
handling to cardiac remodelling 29, cardiomyopathy 30, microvascular disease 31 and heart failure 
32, while chronic activation of HIF-1α in animal models leads to progressive heart failure and 
premature death 33. Elevated HIF-1α was therefore a prerequisite for the threshold against 
which to evaluate our tracers. There is currently no non-invasive method for measuring 
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intracellular HIF-1α; a hypoxia-specific imaging agent which correlates with the onset of 
hypoxia-dependent HIF-1α stabilization, such as we identify in 64CuCTS, is therefore a 
potentially useful development. 
While our isolated heart model is ideal for establishing basic structure-activity relationships of 
new tracers, it is limited in that it cannot inform upon other important pharmacokinetic factors 
like tracer metabolism. Hueting et al. have recently suggested in this Journal that the 
biodistribution and pharmacokinetics of 64Cu-acetate in tumour-bearing mice is similar to that of 
64Cu-ATSM when assessed after 2 or 16 hours, and that 64Cu-acetate exhibits hypoxia 
selectivity in cultured cancer cells, suggesting that Cu-bis(thiosemicarbazone) complexes 
dissociate quickly in vivo, and that the resultant biodistribution observed by PET is that of free 
copper, questioning the validity of 64CuATSM as a hypoxia tracer 34. We and other groups have 
observed no such non-specific uptake up of ionic 64Cu2+ salts in normoxic or hypoxic myocytes 
in culture 15, CHO cells 35, or in isolated buffer perfused hearts 17, 21. The wide variation in 
pharmacokinetics and early biodistributions that the different bis(thiosemicarbazones) have 
been shown to display, with some being hypoxia selective (ATSM, ATS, CTS etc.) and some 
not (PTSM, GTSM), some crossing the blood-brain barrier (GTSM, PTSM, ATSM etc.) and 
some not (ATS)36,37, would also argue against a common non-selective mechanism of early 
tissue uptake. If such a mechanism does exist, it is likely dependent on tracer metabolism, and 
late recirculation of 64Cu2+ in copper transport proteins.  We have recently shown that 
64CuATSM, 64CuCTS and 64CuATS all rapidly wash out of normoxic myocardium in rats in vivo 
to a stable low level within 5 minutes of injection, with no secondary “creep” of non-specific 
cardiac accumulation due to recirculation in the ensuing 30 minutes of imaging 17, and no 
significant 64Cu retention in healthy myocardium by biodistribution after 90 minutes. If secondary 
recirculation of 64Cu occurs at later time points, the time between injection and imaging, and the 
relative in vivo stability of these complexes would be an important consideration in their use and 
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interpretation. Our study and many others which precede it 14, 17, 21 highlight the rapid hypoxia 
selectivity and tissue clearance of these tracers (within 5 minutes from normoxic myocardium 
both ex vivo, and in vivo)17, 38. We would therefore suggest that the rapid kinetics of these 
tracers should be exploited to minimise the potential impact of metabolism and recirculation by 
keeping imaging times short.  
 
We have used 64Cu in these experiments because its 12 hour half life allows us to perform 
several experiments from each batch. However, its half life is not ideal in terms of patient 
exposure, and with a positron yield of only 17.8%, nor is its dosimetry. In contrast, 62Cu 
production does not require a cyclotron, has a half life of only 9.74 min and a 98% positron 
yield. The rapid kinetics that these tracers display would be very well suited to exploiting the 
dose-limiting advantages of 62Cu radiolabelling clinically. We have employed isolated perfused 
hearts in this study because the model allows the accurate and reproducible induction of a 
range of hypoxic severity which would not be possible (or survivable or measurable) in vivo. It 
should of course be noted that tracer pharmacokinetics may be different in blood than in 
aqueous solution, and that the relationship between cardiac workload, arterial blood supply and 
tracer retention are likely to differ from that in vivo. We have, however, demonstrated the 
relative hypoxia selectivities of these tracers perfused under the same conditions, and 64CuCTS 
appears to be a significant improvement upon 64CuATSM in terms of hypoxia sensitivity. 
 
We are currently unable to explain fully why 64CuCTS exhibits better selectivity for low grade 
hypoxia than 64CuATSM. Previous reports have suggested that hypoxia selectivity might be 
primarily governed by redox potential, yet CuATS, CuCTS, CuATSM and CuATSE all have the 
same redox potential (-0.59V versus Ag/AgCl35) and different hypoxia selectivities. It therefore 
appears that while redox potential imparts hypoxia selectivity generally (the non-hypoxia 
selective tracer CuPTSM has a lower redox potential of -0.51V), subtle modification of redox 
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potential is not the only route by which hypoxia selectivity can be fine tuned. We previously 
demonstrated that decreasing tracer lipophilicity increased tracer fast clearance rate, and 
improved hypoxic/normoxic contrast over CuATSM17 (the logP values of CuATSE, CuATSM, 
CuCTS and CuATS are 2.34, 1.61, 1.01 and 0.35 respectively 21, 35). There is a limit to this 
tactic, however, since CuATS, which has the lowest lipophilicity, provided no further gain in 
hypoxia sensitivity at the 30% threshold. We speculate that the subtle balance between redox 
potential, lipophilicity and steric hindrance of redox and ligand exchange reactions governs 
residence time in the cell (and/or its intracellular localisation), and determine the rate at which 
each complex is reduced, reoxidised and dissociated to release its payload.  
  
CONCLUSION 
Hypoxia imaging has the capacity to augment current techniques for identifying viable but at-risk 
myocardium. Diffuse hypoperfusion associated with non-compensated hypertrophy or 
microvascular disease is currently difficult to diagnose by imaging perfusion; specifically imaging 
the resultant hypoxia by PET may be a useful alternative approach. While 64CuATSM seems 
insufficiently sensitive to target myocardium compromised by such low- level survivable hypoxia, 
we identify 64CuCTS as a potentially more suitable PET tracer in this regard. 
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Figure 2 
 
Figure 2: The relationship between hypoxic buffer perfusion and 64Cu radiotracer uptake.  Data 
(mean n=6±SD), represent cardiac 64Cu retention from each tracer for 64CuCTS (closed 
triangles), 64CuATS (open circles), 64CuATSE (open squares), and 64CuATSM (closed triangles) 
as a percentage of injected dose 10 minutes after injection after (A) 5 minutes and (B) 25 
minutes hypoxia. *significantly different from pre-hypoxic control values (p<0.05).  
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Figure 3 
 
Figure 3: The relationship between hypoxic buffer perfusion and cardiac contractility and 
haemodynamics. Data (mean n=6±SD) represent changes in left ventricular developed pressure 
(LVDP), left ventricular end diastolic pressure (LVEDP) and perfusion pressure (PP), after (A) 5 
minutes and (B) 25 minutes hypoxia. *significantly different from pre-hypoxic values (p<0.05). 
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